HCMV

SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford

Retrieved on: 
torsdag, maj 23, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, EBV, Patient, Infection, Epstein–Barr virus, University, Conditional sentence, Safety, Vaccine, Multiple sclerosis, University of Oxford, Blood, Cancer, CSO, HCMV, Jenner Institute, Infectious mononucleosis, Therapy, Antibody

SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, today announced a sponsored research agreement with The University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).

Key Points: 
  • SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, today announced a sponsored research agreement with The University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).
  • EBV is a commonly spread virus that can lead to several serious health conditions including infectious mononucleosis and is linked to various cancers and multiple sclerosis.
  • “This research collaboration is an important step forward on a commonly spread virus with no currently available vaccines or therapeutics for its prevention or spread,” said Mark Leuchtenberger, Chief Executive Officer of SpyBiotech.
  • Under the terms of this agreement, SpyBiotech will provide Oxford researchers with access to the SPYVLP vaccine platform, and the Oxford team will work to advance the research into a Phase 1 clinical trial to be conducted through the University.

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 2, 2024
AIDS, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Infection, HIV Vaccine Trials Network, Administration, Cirrhosis, ASPR, Bangladesh Technical Education Board, Congress, HHS, COVID, EASL, Investment, Safety, Peginterferon-alfa, Abstract, MedRxiv, Development, Hepatitis, GSK, Vir, HCMV, Bill, Data analysis, Influenza, Conditional sentence, HIV, MBA, Metapneumovirus, Vaccine

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
  • The Phase 2 MARCH Part B trial is fully enrolled with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Cash, cash equivalents and investments declined by approximately $118 million during the first quarter of 2024.
  • Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
torsdag, april 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
torsdag, februari 22, 2024
Biotechnology, Pharmaceutical, AIDS, Health, COVID-19, Infectious Diseases, Health Technology, Clinical Trials, Infection, Bangladesh Technical Education Board, RSV, CHB, Influenza, Peginterferon-alfa, HIV Vaccine Trials Network, GSK, Research, Investment, AASLD, HDV, MBA, Cirrhosis, HHS, Administration, Conditional sentence, Hepatology, RNA, Respiratory syncytial virus, ASPR, COVID, Patient, Family, HCMV, Bill, Development, HIV, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
måndag, november 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

Retrieved on: 
torsdag, december 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Vaccine, Infection, Safety, Ageing, Conditional sentence, Hepatitis, HCMV, Cancer, Birth

There is currently no approved vaccine against HCMV.

Key Points: 
  • There is currently no approved vaccine against HCMV.
  • The Phase I trial will be assessing safety and immunogenicity of the company’s HCMV vaccine in two different doses in healthy adults aged 18-50.
  • Target enrollment is approximately 120 participants and clinical data is expected in the first half of 2024.
  • “We see a great need for a vaccine against HCMV, as this virus causes thousands of permanent disabilities in newborns each year.

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

Retrieved on: 
onsdag, september 20, 2023
Vaccine, HIV/AIDS, Conditional sentence, Joint United Nations Programme on HIV/AIDS, HIV, Public, National Institute of Allergy and Infectious Diseases, Clinical trial, Research, Antibody, Bill & Melinda Gates Foundation, Person, Bangladesh Technical Education Board, Tuberculosis, Clinical research, Immune system, Bill, HVTN, HIV Vaccine Trials Network, NIAID, Health, HCMV, UNAIDS, Infection, Safety, Disease, Malaria, Pharmaceutical industry

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). The Company expects initial data from the Phase 1 trial in the second half of 2024.

Key Points: 
  • The Company expects initial data from the Phase 1 trial in the second half of 2024.
  • VIR-1388 was developed using applied learnings from VIR-1111, the Company’s initial investigational proof-of-concept HIV T cell vaccine based on HCMV.
  • The Phase 1 trial of VIR-1388 will take place in both domestic and international sites within the federally funded HIV Vaccine Trials Network (HVTN) as study HVTN 142.
  • The randomized, double-blind, placebo-controlled Phase 1 trial (NCT05854381) is evaluating the safety, reactogenicity and immunogenicity of three different doses of VIR-1388 compared with placebo.

SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01

Retrieved on: 
onsdag, september 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Vaccine, Health care, Conditional sentence, Clinical trial, Hepatitis, Cancer, CTA, Infection, HCMV, Birth, MHRA, Pharmaceutical industry

SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K.

Key Points: 
  • SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K.
  • Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP01, a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology.
  • “Submission of our clinical trial application to evaluate SPYVLP01 marks important progress in the fight against the HCMV virus, a leading infectious cause of congenital abnormalities,” said Sumi Biswas, Ph.D., President and Chief Scientific Officer of SpyBiotech.
  • The first participant is expected to be dosed later this year with clinical data emerging in the first half of 2024.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
fredag, augusti 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
torsdag, augusti 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.